Inhibitory effect of Huangqi Zhechong decoction on liver fibrosis in rat
- PMID: 15259087
- PMCID: PMC4724985
- DOI: 10.3748/wjg.v10.i15.2295
Inhibitory effect of Huangqi Zhechong decoction on liver fibrosis in rat
Abstract
Aim: To assess the inhibitory effect of Huangqi Zhechong decoction on hepatic fibrosis in rats induced by CCl(4) plus alcohol and high fat low protein diet.
Methods: Male SD rats were randomly divided into hepatic fibrosis model group, control group and 3 treatment groups consisting of 12 rats in each group. Except for the normal control group, all the rats were subcutaneously injected with CCl(4) at a dosage of 3 mL/kg. In 3 treated groups, either high-dose group (9 mL/kg), or medium-dose group (6 mL/kg), or low-dose group (3 mL/kg) was daily gavaged with Huangqi Zhechong decoction, and saline vehicle was given to model and normal control rats. Enzyme-linked immunosorbent assay (ELISA) and biochemical examinations were used to determine the changes of alanine aminotransferase (ALT), aspartate aminotransferase (AST), hyaluronic acid (HA), laminin (LN), type-III-procollagen-N-peptide (PIIIP), and type IV collagen content in serum, and hydroxyproline (Hyp) content in liver after sacrificing the rats. Pathologic changes, particularly fibrosis were examined by hematoxylin and eosin (HE) and Van Gieson staining.
Results: Compared with the model control group, serum ALT, AST, HA, LN, PIIIP and type IV collagen levels dropped markedly in Huangqi Zhechong decoction groups, especially in the medium-dose Huangqi Zhechong decoction group (1 954+/-576 U/L vs 759+/-380 U/L, 2 735+/-786 U/L vs 1 259+/-829 U/L, 42.74+/-7.04 ng/mL vs 20.68+/-5.85 ng/mL, 31.62+/-5.84 ng/mL vs 14.87+/-1.45 ng/mL, 3.26+/-0.69 ng/mL vs 1.47+/-0.46 ng/mL, 77.68+/-20.23 ng/mL vs 25.64+/-4.68 ng/mL, respectively) (P<0.05). The Hyp content in liver tissue was also markedly decreased (26.47+/-11.24 mg/mgprot vs 9.89+/-3.74 mg/mgprot) (P<0.01). Moreover, the stage of the rat liver fibrosis in Huangqi Zhechong decoction groups was lower than that in model group, and more dramatic drop was observed in medium-dose Huangqi Zhechong decoction group (P<0.01).
Conclusion: Huangqi Zhechong decoction can inhibit hepatic fibrosis resulted from chronic liver injure, retard the development of cirrhosis, and notably ameliorate the liver function. It may be a safe and effective therapeutic drug for patients with fibrosis.
Figures

Similar articles
-
Preventive effect of Qianggan-Rongxian Decoction on rat liver fibrosis.World J Gastroenterol. 2008 Jun 14;14(22):3569-73. doi: 10.3748/wjg.14.3569. World J Gastroenterol. 2008. PMID: 18567088 Free PMC article.
-
Inhibitory effects of saikosaponin-d on CCl4-induced hepatic fibrogenesis in rats.World J Gastroenterol. 2007 Jan 28;13(4):557-63. doi: 10.3748/wjg.v13.i4.557. World J Gastroenterol. 2007. PMID: 17278221 Free PMC article.
-
Melatonin ameliorates experimental hepatic fibrosis induced by carbon tetrachloride in rats.World J Gastroenterol. 2009 Mar 28;15(12):1452-8. doi: 10.3748/wjg.15.1452. World J Gastroenterol. 2009. PMID: 19322917 Free PMC article.
-
Preclinical evidence of Yinchenhao decoction on cholestasis: A systematic review and meta-analysis of animal studies.Phytother Res. 2021 Jan;35(1):138-154. doi: 10.1002/ptr.6806. Epub 2020 Sep 25. Phytother Res. 2021. PMID: 32975338
-
A meritorious integrated medical regimen for hepatic fibrosis and its complications via the systematic review and meta-analysis for Dahuang Zhechong pill-based therapy.Front Med (Lausanne). 2022 Oct 14;9:920062. doi: 10.3389/fmed.2022.920062. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36314011 Free PMC article.
Cited by
-
Inhibitory effect of emodin and Astragalus polysaccharide on the replication of HBV.World J Gastroenterol. 2009 Dec 7;15(45):5669-73. doi: 10.3748/wjg.15.5669. World J Gastroenterol. 2009. PMID: 19960563 Free PMC article.
References
-
- McCaughan GW, Gorrell MD, Bishop GA, Abbott CA, Shackel NA, McGuinness PH, Levy MT, Sharland AF, Bowen DG, Yu D, et al. Molecular pathogenesis of liver disease: an approach to hepatic inflammation, cirrhosis and liver transplant tolerance. Immunol Rev. 2000;174:172–191. - PubMed
-
- Okazaki I, Watanabe T, Hozawa S, Arai M, Maruyama K. Molecular mechanism of the reversibility of hepatic fibrosis: with special reference to the role of matrix metalloproteinases. J Gastroenterol Hepatol. 2000;15 Suppl:D26–D32. - PubMed
-
- Jung SA, Chung YH, Park NH, Lee SS, Kim JA, Yang SH, Song IH, Lee YS, Suh DJ, Moon IH. Experimental model of hepatic fibrosis following repeated periportal necrosis induced by allylalcohol. Scand J Gastroenterol. 2000;35:969–975. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical